The Biotime ST2 Rapid Quantitative Test measures soluble ST2, a biomarker belonging to the interleukin-1 receptor family, which reflects cardiac stress and myocardial fibrosis. Elevated levels of sST2 are closely associated with adverse cardiac remodeling and poor outcomes in both acute and chronic heart failure patients.

Recognized as a Class II indication for heart failure prognosis, ST2 plays an essential role in the evaluation of various cardiovascular diseases, including coronary artery disease, myocardial infarction, atherosclerosis, ischemic stroke, obesity, and diabetes.

Biotime’s test provides accurate results within 15 minutes, making it suitable for use in clinical laboratories, cardiology units, and emergency departments, where timely and reliable data is critical for patient management.